Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Events Clear all
Not listed No phase listed Observational

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

NCT03155802
View directory record Official record
Conditions
Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy, Biomarkers, Echocardiography
Interventions
Not listed
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

NCT00024427
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, triacetyluridine
Drug
Lead sponsor
Wellstat Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
26
States / cities
Birmingham, Alabama • Burbank, California • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Not applicable Interventional

Systematic Light Exposure for Fatigue in Breast Cancer Patients

NCT03217201
View directory record Official record
Conditions
Cancer-related Problem/Condition, Fatigue, Circadian Rhythm Disorders
Interventions
Light Glasses (Experimental), Light Glasses (Comparison)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

NCT05137067
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell), Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo, Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
Dietary Supplement · Drug
Lead sponsor
Optimal Health Research
Other
Eligibility
25 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 13, 2026, 8:33 AM EDT
Completed No phase listed Observational

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

NCT06089967
View directory record Official record
Conditions
Cancer, Immune-related Adverse Event
Interventions
Medical chart review
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Not applicable Interventional Results available

Video-laryngoscope With a Novel Video-stylet for Difficult Intubation

NCT01215695
View directory record Official record
Conditions
Difficult Endotracheal Intubation
Interventions
aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD), Control
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 13, 2026, 8:33 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

NCT04148430
View directory record Official record
Conditions
B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
Interventions
Anakinra
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of Non-Invasive Positive Pressure Ventilation in Patients With Severe Obesity Undergoing Upper Endoscopy Procedures

NCT03529461
View directory record Official record
Conditions
Severe Obesity, Hypoxia
Interventions
Non-invasive positive pressure ventilation through nasal mask, Rescue non-invasive positive pressure ventilation through nasal mask, Secondary rescue maneuvers
Device · Other
Lead sponsor
Bristol Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bristol, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 13, 2026, 8:33 AM EDT
Recruiting Phase 3 Interventional

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
124
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 13, 2026, 8:33 AM EDT
Active, not recruiting Not applicable Interventional

nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

NCT05283629
View directory record Official record
Conditions
Chemo-brain, Chemotherapy-Related Cognitive Impairment
Interventions
Neuroplasticity-based Computerized Cognitive Remediation, Active Control Condition
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
35 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

NCT01190189
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
GSK580299 (Cervarix)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
26 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
21
States / cities
Aurora, Colorado • Golden, Colorado • Coral Gables, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Phase 2Phase 3 Interventional

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

NCT05755035
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
TAK-881, HYQVIA
Biological
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Irvine, California • Walnut Creek, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 13, 2026, 8:33 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Corneal Blindness
Interventions
Infliximab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

NCT00002759
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Neutropenia, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclosporine, irinotecan hydrochloride, phenobarbital
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 13, 2026, 8:33 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 13, 2026, 8:33 AM EDT
Completed No phase listed Observational

Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders

NCT00255671
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Radiation Toxicity
Interventions
Questionnaire
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 13, 2026, 8:33 AM EDT
Recruiting Phase 2 Interventional

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

NCT05559164
View directory record Official record
Conditions
Cardiac Toxicity, Early-stage Breast Cancer
Interventions
Lipitor 40mg Tablet
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 13, 2026, 8:33 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
COVID-19 vaccines
Biological
Lead sponsor
Mebo Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Miami, Florida • Vonore, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 13, 2026, 8:33 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 13, 2026, 8:33 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

COVID-19 Reactogenicity

NCT07051031
View directory record Official record
Conditions
COVID-19
Interventions
Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
Drug
Lead sponsor
Marcel Curlin
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 13, 2026, 8:33 AM EDT
Recruiting Phase 4 Interventional

The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial

NCT05618353
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Colchicine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 13, 2026, 8:33 AM EDT
Withdrawn Phase 4 Interventional

Can Nitrous Oxide (Laughing Gas) be Used as a Sedative for GI Endoscopy Procedures?

NCT05396144
View directory record Official record
Conditions
Endoscopy, Colonoscopy
Interventions
5% inhaled nitrous oxide, 50% inhaled nitrous oxide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Not applicable Interventional

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

NCT05403736
View directory record Official record
Conditions
Cancer
Interventions
Cardiac Aggressive Risk MitigAtion Plan
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 13, 2026, 8:33 AM EDT
Completed Phase 3 Interventional

Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

NCT05439616
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Anaheim, California • Imperial, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 13, 2026, 8:33 AM EDT